Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be clinically effective to date. We explore the resistance mechanisms uniquely employed by malignant...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Ponz-Sarvise, Mariano, Corbo, Vincenzo, Tiriac, Hervé, Engle, Dannielle D., Frese, Kristopher K., Oni, Tobiloba E., Hwang, Chang-Il, Öhlund, Daniel, Chio, Iok In Christine, Baker, Lindsey A., Filippini, Dea, Wright, Kevin, Bapiro, Tashinga E., Huang, Pearl, Smith, Paul, Yu, Kenneth H., Jodrell, Duncan I, Park, Youngkyu, Tuveson, David A.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858952/
https://ncbi.nlm.nih.gov/pubmed/31492749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1398
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares